what is the guideline according to australian medical council for crohn's disease
Reading File
Finding Sources
Searching the Web
Australian Medical Council AMC Crohn's disease guidelines management
Searching PubMed
"Crohn disease"[MeSH Terms] AND "practice guideline"[pt]
Reading File
Searching the Web
AMC MCQ Crohn's disease clinical features diagnosis treatment Australia exam
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have comprehensive information to provide a thorough answer. Here is what's important to note first: the Australian Medical Council (AMC) does not publish its own disease-specific clinical guidelines for conditions like Crohn's disease. Rather, the AMC is an assessment body for international medical graduates (IMGs). The AMC MCQ examination tests candidates on the principles and practice of medicine as applied in the Australian community, drawing on established guidelines (ACG, ECCO, GESA — Gastroenterological Society of Australia) and standard textbook knowledge.
Crohn's Disease — AMC Examination Framework
Important Clarification
The Australian Medical Council does not issue condition-specific clinical guidelines. Its MCQ exam tests medical knowledge relevant to Australian clinical practice, including IBD management. The relevant Australian clinical guideline body for gastroenterology is the Gastroenterological Society of Australia (GESA). The AMC recommends using journals such as Australian Family Physician and Australian Prescriber alongside standard textbooks. The content below reflects what the AMC exam expects candidates to know about Crohn's disease.
1. Definition & Pathology
Crohn's disease (CD) is a chronic, relapsing, transmural inflammatory disorder that may affect any part of the GI tract from mouth to anus, with discontinuous ("skip") lesions. Unlike ulcerative colitis, which is mucosal only, CD involves all layers of the bowel wall (transmural).
- Most common site: Terminal ileum + proximal colon (~40%), but may be isolated to ileum (30%), colon (25%), or upper GI tract
- Hallmark microscopic feature: Non-caseating granulomas (present in ~60%)
- Macroscopically: "cobblestone" mucosa, fissuring ulcers, skip lesions, "fat wrapping"
2. Clinical Features
Intestinal
| Feature | Detail |
|---|---|
| Abdominal pain | RLQ most common (mimics appendicitis) |
| Diarrhea | Non-bloody (unlike UC), may be nocturnal |
| Weight loss / malnutrition | Due to malabsorption + reduced intake |
| Perianal disease | Fissures, fistulae, abscesses, skin tags |
| Fistulae | Enterocutaneous, rectovaginal, enterovesical |
| Strictures / obstruction | From fibrosis |
| Abscesses | Intra-abdominal |
Extraintestinal Manifestations (more common in CD than UC)
- Joints: Peripheral arthritis, ankylosing spondylitis, sacroiliitis
- Eyes: Uveitis, episcleritis
- Skin: Erythema nodosum, pyoderma gangrenosum
- Mouth: Aphthous ulcers
- Liver: Primary sclerosing cholangitis (less common than UC), fatty liver
3. Diagnosis
Investigations
| Investigation | Finding / Use |
|---|---|
| Fecal calprotectin | Cutoff >50–100 mg/g distinguishes inflammatory from non-inflammatory bowel disease; sensitive marker of intestinal inflammation |
| CRP / ESR | Elevated in active disease; CRP correlates with clinical + endoscopic activity |
| Colonoscopy + biopsy | Gold standard — shows skip lesions, aphthous ulcers, cobblestoning; biopsy for granulomas |
| CT/MR Enterography | Assesses small bowel extent, mural thickening, "comb sign" (engorged peri-enteric vasculature), fistulae, abscesses |
| Intestinal ultrasound | Non-invasive, radiation-free adjunct for diagnosis and monitoring |
| ASCA | Anti-Saccharomyces cerevisiae antibodies positive in >50% of CD patients; specificity >95%, sensitivity <50% |
| FBC | Anaemia (iron deficiency, B12 deficiency from terminal ileal disease) |
| Serum B12 | Specifically decreased in terminal ileal CD |
Disease Activity Scoring
- CDAI (Crohn's Disease Activity Index): Remission = CDAI <150; response = decrease ≥100 points
- Activity classified as mild, moderate, or severe based on response to therapy, abdominal tenderness, mass/obstruction, malnutrition, weight loss, anaemia
4. Medical Management
Stepwise Approach (current practice favours early advanced therapy — "top-down" over "step-up")
Mild Disease
- Oral budesonide (for ileocaecal CD) — preferred over prednisolone due to lower systemic side effects
- Mesalazine (5-ASA) — limited efficacy in CD (more effective in UC); may be used in mild colonic CD
- Metronidazole/ciprofloxacin — for perianal disease or infection complications; NOT for luminal CD maintenance
Moderate Disease
- Prednisolone (systemic corticosteroids) — for induction of remission; NOT for maintenance (steroid-dependent/refractory disease requires escalation)
- Azathioprine / 6-mercaptopurine (6-MP) — immunomodulators; for maintenance of remission; onset 3–6 months; check TPMT before starting
- Methotrexate — alternative immunomodulator, especially in those intolerant of thiopurines; requires folate supplementation
Severe / Refractory Disease — Biologics
| Drug | Class | Use |
|---|---|---|
| Infliximab (IV) | Anti-TNF-α | Induction + maintenance; also for fistulising disease |
| Adalimumab (SC) | Anti-TNF-α | Induction + maintenance |
| Vedolizumab | Anti-integrin (α4β7) | Gut-selective; maintenance |
| Ustekinumab | Anti-IL-12/23 (p40) | Induction + maintenance |
| Risankizumab | Anti-IL-23 (p19) | Newer agent |
Key AMC point: The drugs of choice for Crohn's disease are now immunomodulators and biologics, particularly anti-TNF-α agents. Current guidelines suggest against requiring failure of conventional therapy before initiating advanced therapy in appropriate patients (2025 ACG guideline).
Fistulising Disease
- Infliximab — most evidence; induces and maintains fistula closure
- Adjunct: antibiotics (metronidazole), seton placement, examination under anaesthesia (EUA) for complex perianal fistulae
5. Nutritional Therapy
- Exclusive Enteral Nutrition (EEN): Comparable to steroids for induction of remission, especially in children; first-line in paediatric CD
- Crohn's Disease Exclusion Diet (CDED) + partial enteral nutrition: Comparable to EEN in mild disease
- All IBD patients should have access to a dietitian
- Vitamin B12 supplementation for terminal ileal disease/resection
- Iron supplementation for anaemia
6. Surgical Management
Indications for surgery:
- Complications: Intra-abdominal abscess, medically intractable fistula, fibrotic stricture with obstruction, toxic megacolon, dysplasia/cancer
- Medically refractory disease (especially steroid-dependent/refractory)
- Growth failure in children
Key surgical principles:
- Bowel-conserving surgery — guiding principle (wide margins do NOT reduce recurrence; repeated resections risk short bowel syndrome)
- Most common operation: Ileocaecal resection ± laparoscopic approach
- Surgery rates: ~16% at 1 year, 33% at 5 years, 47% at 10 years from diagnosis (though declining with better medical therapy)
- Surgery is not curative — recurrence rate 20–50% post-resection
- Percutaneous drainage for intra-abdominal abscesses, followed by elective resection in selected patients
7. Monitoring & Treat-to-Target
- Mucosal healing (endoscopic remission) is the therapeutic target beyond symptom resolution
- Biomarkers (CRP, fecal calprotectin) used to track disease activity — symptoms alone should not guide therapy
- Colonoscopic surveillance for colorectal cancer in patients with Crohn's colitis
- Bowel cancer risk increased — surveillance colonoscopy recommended after 8–10 years of colonic disease
8. Complications to Know for AMC
| Complication | Management |
|---|---|
| Toxic megacolon (transverse colon >6 cm + toxic patient) | IV fluids, IV steroids, bowel rest, surgical consult |
| Short bowel syndrome | After multiple resections; requires specialist nutrition |
| B12 deficiency | Terminal ileal disease or resection |
| Stricture → SBO | Medical (anti-inflammatory if active), endoscopic dilation, or surgery |
| Fistulae | Antibiotics + infliximab ± surgery |
| Perianal abscess | Drainage + antibiotics; seton for fistulae |
Key Differentials (CD vs UC — AMC favourite)
| Feature | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Distribution | Entire GI tract, skip lesions | Colon only, continuous from rectum |
| Depth | Transmural | Mucosal only |
| Rectal involvement | Often spared | Always involved |
| Fistulae | Common | Rare |
| Granulomas | Yes (~60%) | No |
| Diarrhea | Non-bloody (usually) | Bloody (hallmark) |
| ASCA | Positive >50% | Less common |
| pANCA | Less common | Positive ~60% |
Sources:
- Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 11th ed. (Chapters 115–116)
- Rosen's Emergency Medicine, 9th ed. (Chapter 81)
- Swanson's Family Medicine Review — ACG Clinical Guideline reference (Lichtenstein et al.)
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment (2024) [PMID: 38877997]
- ACG Clinical Guideline: Management of Crohn's Disease in Adults (2025) [PMID: 40701562]
- Gastroenterological Society of Australia (GESA) — Australian-specific IBD practice guidance
- AMC MCQ Examination Specifications
This is a shared conversation. Sign in to Orris to start your own chat.